Data safety monitoring boards: Legal and ethical considerations for research accountability

Accountability in Research

Volumn 17, Issue 1, 2010, Pages 30-50

  Tereskerz, Patricia M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Data safety monitoring; Ethics; Law

Indexed keywords

ARTICLE; CLINICAL TRIAL; ETHICS; FOOD AND DRUG ADMINISTRATION; HUMAN; LEGAL ASPECT; LEGAL LIABILITY; MALPRACTICE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; HUMANS; LIABILITY, LEGAL; MALPRACTICE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 75749093972     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989620903520313     Document Type: Article

References (49)

1. Abate, T. (2002). Experiments on humans: Business of clinical trials soars, by risks unknown. San Francisco Chronicle, 4: A1.
2. Angell, M. (2004). The Truth about Drug Companies. New York: Random House.
3. Associated Press. (2003). JAMA Decries Early End to Study. Wall Street Journal, April:D4.
4. Bolland, K., and Whitehead, J. (2000). Formal approaches to safety monitoring of clinical trials in life-threatening conditions. Statistics in Medicine, 19:2899-2917.
5. Bruce, M. P., and Rennie, D. (2003). Stopping medical research to save money. A broken pact with researchers and patients. JAMA, 289:2128-2131.
6. Cairns, J. A., Hallstrom, A., Held, P. (2001). Should all trials have a data safety and monitoring committee? American Heart Journal, 141:156-163.
7. CFR 50.24(a)(7)(iv).
8. CFR 21 Section 312.3(b)
9. Data Monitoring Committees, AKA Data/safety monitoring boards some changes are in the wind. Available at: http:www.research.umn.edu/irb/members/DSMBPosting.pdf. Last accessed January 13, 2007.
10. DeMets, D. L., Pocock, S., Julian, D. G. (1999). The agonizing negative trend in monitoring clinical trials. Lancet, 354:1983-1988.
11. DeMets, D.L., Fleming, T. R., Rockhold, F., Massie, B., Merchant, T., Meisel, A., Mish-kin, B., Wittes, J., Stump, D., Califf, R. (2004). Liability issues for data monitoring committee members. Clinical Trials, 1:525-531.
12. DHHS. Office of Inspector General. Institutional Review Boards: A Time for Reform. OEI-01-97-00193. June 1998.
13. FDA Draft Guidance. Guidance for Clinical Trial Sponsors. On the Establishment and Operation of Clinical Trail Data Monitoring Committees. Available at: http:// www.fda.gov/cber/gdlns/clindatomon.htm.htm. Last accessed December, 2005.
14. FDA Guidance on Clinical Trial Data Monitoring Committees (DSMBs). Tuesday, November 27, 2001, p. 26.
15. Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Open Public Meeting FDA Guidance on Clinical Trial Data Monitoring Committees. Nov. 27, 2001. Transcript available from FDA Web site at: http://www.fda.gov, p. 25.
16. 45 CFR Section 46.116;
17. Stalcup, C. (2004) Reviewing the review boards: Why institutional review board liability does not make good business sense. Washington Law Quarterly, 82:1593-1619.
18. Foubister, V. (2001). Clinical trial patients sue IRB Members. American Medical News, 44 (8): http://www.ama-assn.org/amednews/2001/02/26/prsb0226.htm
19. Friter v. Iolab Corp. 414 Pa. Super. 622, 607 A.2d 1111 (1992).
20. Gregg v. Kane. 1997 WL 570909 (E.D. Pa. 1997).
21. Grimes v. Kennedy Krieger Institute, Inc. 366 Md. 29, 782 A.2d 807 (2001).
22. Heart Special Project Committee. (1988). Organization, review and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Controlled Clinical Trials, 9:137-148.
23. Heinrich v. Sweet. 308 F.3d 48 (1st Cir. 2002.)
24. Hillman, D. W., and Louis, T. A. (2003). DSMB case study: Decision making when a similar clinical trial is stopped early. Controlled Clinical Trials, 24:85-91.
25. Jansson, R. L. (2003). Researcher liability for negligence in human subject research: Informed consent and researcher malpractice actions. Wash. L. Rev., 78:229-263.
26. Johnson v. Kosmos Portland Cement Co., 64 F.2d 193 (6th Cir. 1933).
27. Kaplan, A. M., Gilpin, J. T., Holbrook, D. A., and Jabs, C. L. (2003). Meinert and for the Studies of Ocular Complications of AIDS Research Group. Data and safety monitoring board deliberations resulting in the early termination of the mono-clonal antibody cytomegalovirus retinitis trial. Controlled Clinical Trials, 24:92-98.
28. Kaplan, S., and Brownlee, S. (1999). Dying for a cure: Why cancer patients often turn to risky experimental treatments-and wind up paying with their lives. U.S. News & World Report, Oct. 11, p. 34.
29. Katz, H. S., and McCarroll, B. (2004). Clinical trials: Alternative revenue steram or just another potential lawsuit. Health Law, 16(6):1-12.
30. Kus v. Sherman Hosp. 644 N.E.2d 1214, 1220-21) Ill. App. Ct.(1995); Friter v. Iolab Corp., 607 A.2d 1111, 1113 (Pa. Super. Ct. 1992); Weiss v. Solomon, 1989 RJQ 731 (Can.); Bryant v. HC Health Servs. of No. Tenn., 15 S.W.3d 804, 810-11 (Tenn. 2000).
31. Lowe, C. N. (2007). Clinical trial litigation. Med. Malpractice L. and Strategy, 24(4):1.
32. Miller, M. (2006). Increased scrutiny [sic] clinical trial contracts-probing indemnification. DRI for Def., 48(4):8.
33. Morreim, E. H. (2005). Clinical trial litigation: Practical realities as seen from the trenches. Accountability in Res., 12:47-67.
34. NCI disclosure of walkout by DSMB may be harmful, improper, experts say. (2004). The Cancer Letter, 30:1-5.
35. NIH Guide: NIH Policy for Data and Safety Monitoring. June 10, 1998. Available at: http://grants.nih.gov.
36. NIH Guide. Further Guidance on a Data and Safety Monitoring for Phase I and Phase II Trials. June 5, 2000. Available at: http://grants2.nih.gov.
37. Resnik, D. B. (2004). Liability for institutional review boards. Journal Legal Medicine, 25:131-184.
38. Restatement of Torts 2d Section 496B.
39. Rue, J. D. (2003). Returning to the roots of the bramble bush: The "but for" test regains primacy in causal analysis in the American Law Institute's proposed Restatement (Third) of Torts. Fordham L. Rev., 71:2679-2733.
40. Stalcup, C. M. (2004). Reviewing the review boards: Why institutional review board liability does not make good business sense. Wash. U. L.Q., 82:1593-1619.
41. Slutsky, A. S., Lavery, J. V. (2004). Data safety and monitoring boards. NEJM 350:1143-1147.
42. Stolberg, S. G. (2000). Teenager's death is shaking up field of human gene-therapy experiments. New York Times. January 27. WL 12394777; The Financier. No Wonder They Call the Place 'Mother Hutch.' March 14, 2001. Seattle Times, p. A9.
43. Taylor, C. W., Googasian, G. A., Falk, A. S. (2006). Chapter 9. Defenses and Immunities I. Defenses Generally C. Comparative Negligence § 9:296. General rule--Comparative negligence doing more than replacing contributory negligence. Michigan Practice Guide: Torts Database updated October.
44. Taylor, C. W., Googasian, G. A., Falk, A. S. (2006). Chapter 9. Defenses and Immunities II. Miscellaneous Immunities from Liability (Nongovernmental Tortfeasors) A. Miscellaneous Immunities from Liability (Nongovernmental Tortfeasors) § 9:591. Michigan Practice Guide: Torts Database updated October.
45. 21 CFR 312.32(c) 2004.
46. U.S. Food and Drug Administration (FDA). Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. Section 2.1-2.3. March 2006.
47. Wallmuth v. Rapides Parish School Board. 813 So. 2d 341 (La. 2002).
48. West Virginia Central RR Co. v. Fuller. 96 Md. 652, 666, 54 A. 669 671 (1903).
49. Whitlock v. Duke. 637 F. Supp.1463 (MDNC 1986).